Jason Gerberry is a Managing Director on the US Specialty Pharma and Smid Cap Biotech equity research teams. Gerberry joined the firm in August 2017, prior to which he was a senior analyst at Leerink from 2011-17 and an associate analyst on the pharmaceutical equity research team (2009-11). In each of the last four years he has ranked in the Institutional Investor All-America Research Poll for Specialty Pharma, ranking third in 2021-23. Gerberry has also been a meaningful contributor to the BofA SMID Biotech team, which has ranked Runner Up in each of the last three II polls (2021-23). He started his career in pharma strategy consulting at Defined Health (2004-06) and further refined his understanding of the biopharma industry working at Forest Laboratories on the New Product License and Acquisition team (2006-08). From 2000-04, Gerberry studied at Case Western Reserve University where he earned dual Juris Doctor and MBA degrees. He is based in New York. For more information about any awards cited, visit https://rsch.baml.com/awards.